MAPK1 and cancer: Thus, the RASopathy- and cancer-associated mutations do not simply lead to quantitative differences in the basal kinase activity of MEK1, but they induce qualitative differences in the spatiotemporal dynamics of ERK signaling and in consequent gene expression profiles, thereby leading to the development of distinct clinical manifestations (Supplementary Fig. 6e).